**Core Concept**
Imatinib, a tyrosine kinase inhibitor, is used in the treatment of Chronic Myeloid Leukemia (CML). It targets the BCR-ABL tyrosine kinase, which is a result of the Philadelphia chromosome abnormality. This abnormality occurs due to a translocation between chromosomes 9 and 22, creating a fusion gene that codes for the BCR-ABL protein.

**Why the Correct Answer is Right**
Imatinib works by selectively inhibiting the BCR-ABL tyrosine kinase, which is responsible for the uncontrolled proliferation of leukemia cells. This inhibition prevents the phosphorylation of downstream signaling molecules, thereby reducing the growth and survival signals of the leukemia cells. Imatinib binds to the ATP-binding site of the BCR-ABL tyrosine kinase, thereby blocking its activity. This results in the apoptosis of leukemia cells and a reduction in the tumor burden.

**Why Each Wrong Option is Incorrect**
**Option A:** Imatinib does not act as a topoisomerase inhibitor, which is a mechanism of action of other chemotherapeutic agents like etoposide and doxorubicin.
**Option B:** Imatinib does not work by inhibiting the mTOR pathway, which is a downstream signaling pathway involved in cell proliferation and survival.
**Option C:** Imatinib does not act as a proteasome inhibitor, which is a mechanism of action of other chemotherapeutic agents like bortezomib.

**Clinical Pearl / High-Yield Fact**
Imatinib is a classic example of a targeted therapy, which is a type of cancer treatment that specifically targets the molecular mechanisms driving cancer cell growth and survival.

**Correct Answer: A. Imatinib acts by selectively inhibiting the BCR-ABL tyrosine kinase.**